Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-04-08

Clinical Trial Update: A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA [Phase 3]

View source ↗

Summary

Phase I/III trial comparing subcutaneous CT-P13 to intravenous CT-P13 in active rheumatoid arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CT-P13 (infliximab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-04-08